Muhammad Jahangir Hossen,Seung Cheol Kim,Sungjae Yang et al.
Muhammad Jahangir Hossen et al.
Introduction: 3-Phosphoinositide-dependent kinase 1 (PDK1) is a master regulator of the AGC protein kinase family and is a critical activator of multiple pro-survival and oncogenic protein kinases, for which it has garner...
Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014) [0.03%]
瞬时受体电位香草酸型1拮抗剂专利回顾（2011-2014）
Yoonji Lee,Sunhye Hong,Minghua Cui et al.
Yoonji Lee et al.
Introduction: Transient receptor potential vanilloid type 1 (TRPV1) is a nonselective cation channel that can be activated by noxious heat, low pH and vanilloid compounds such as capsaicin. Since TRPV1 acts as an integrat...
Andrea Desogus,Silvia Schenone,Chiara Brullo et al.
Andrea Desogus et al.
Introduction: Breakpoint cluster region Abelson (Bcr-Abl) tyrosine kinase (TK) is a constitutively activated cytoplasmic TK and is the underlying cause of chronic myeloid leukemia (CML). To date, imatinib represents the f...
Dzmitry Shcharbin,Natallia Shcharbina,Antos Shakhbazau et al.
Dzmitry Shcharbin et al.
Introduction: The beginning of the nano-era started with the appearance of artificial nanosized supramolecular systems called nanomaterials and nanoparticles (NPs). ...
Nitroimidazole derivatives: a patent review of US 2014/0141084 A1 [0.03%]
硝基咪唑衍生物美国专利2014/0141084A1评审
Peng-Cheng Lv,Hai-Liang Zhu
Peng-Cheng Lv
Nitroimidazoles and their derivatives have drawn continuing interest over the years because of their varied biological activities and their recently found applications in drug development for antimicrobial chemotherapeutics and antiangiogen...
Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344 [0.03%]
一种结合肌肉生长抑制素的纤连蛋白基支架结构域多肽专利分析：WO2014043344A1
Ryan G Walker,Thomas B Thompson
Ryan G Walker
Muscular dystrophies (MD) are commonly characterized by progressive loss of muscle mass and function. It is hypothesized that therapeutic blockade of the TGF-β ligand myostatin, a negative regulator of muscle mass, will stimulate muscle gr...
Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension [0.03%]
WO2014132220选择性PDGFR抑制剂治疗肺动脉高压的评估研究论文
Peter Norman
Peter Norman
Introduction: Pulmonary arterial hypertension (PAH) is a rare disease currently treated by a range of vasodilator agents and/or endothelin antagonists. Inhibition of platelet derived growth factor receptor (PDGFR) kinases...
Potential pharmacological uses of chalcones: a patent review (from June 2011 - 2014) [0.03%]
查爾康因的潛在藥理用途：2011年6月-2014年專利回顧
Maria João Matos,Saleta Vazquez-Rodriguez,Eugenio Uriarte et al.
Maria João Matos et al.
Introduction: Chalcones are one of the major classes of naturally occurring compounds. A large number of synthetic routes have been reported for the synthesis of chalcones, the most classical and general being the Claisen...
Therapeutic potential of benzothiazoles: a patent review (2010 - 2014) [0.03%]
苯并噻唑的治疗潜力：专利回顾(2010-2014)
Ahmed Kamal,Mohammed Ali Hussaini Syed,Shaheer Malik Mohammed
Ahmed Kamal
Introduction: Benzothiazole is a versatile fused heterocyclic scaffold with extensive pharmaceutical applications. Several benzothiazole derivatives possess broad spectrum of antimicrobial, analgesic, anti-inflammatory, a...
Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014) [0.03%]
褪黑素及其衍生物的治疗应用专利回顾（2012-2014）
Silvia Rivara,Daniele Pala,Annalida Bedini et al.
Silvia Rivara et al.
Introduction: Melatonin is a neurohormone involved in the regulation of circadian rhythms, with potent antioxidant activity. It has a wide functional repertoire, with effects almost on all tissues and organs. It is mainly...